On Friday, Shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), skyrocketed 41.69% to $9.89, hitting its highest level.
Drugmaker Baxalta is in talks to buy Ariad Pharmaceuticals to boost its oncology business, Bloomberg stated, citing people familiar with the matter.
Talks continue with Ariad, a developer of leukemia and lung-cancer treatments, but there is no certainty a deal will be reached, Bloomberg said, citing the people.
In a report earlier on Friday, Bloomberg said Baxalta was working with bankers to buy an unidentified U.S.-based hematology and oncology specialist valued at about $2 billion.
Baxalta is being pursued by drugmaker Shire, which has made a $30 billion bid for the company.
Baxalta, which was spun off from Baxter International in July, declined to comment on the Bloomberg report.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
Shares of Twenty-First Century Fox, Inc. (NASDAQ:FOXA), inclined 0.43% to $27.92, during its last trading session.
Twenty-First Century Fox, Inc. (NASDAQ:FOXA) shares are predictable to touch $37.54 in the short term. This short-term price target has been shared by 14 analysts. However, the standard deviation of short-term price estimate has been valued at 2.83. The target price could hit $45 on the higher end and $34 on the lower end.
Twenty-First Century Fox, Inc. operates as a diversified media and entertainment company worldwide. It operates through Cable Network Programming; Television; Filmed Entertainment; and Other, Corporate and Eliminations segments.
Finally, Medtronic plc (NYSE:MDT), ended its last trade with 0.05% gain, and closed at $73.56.
The board of directors of Medtronic approved the fiscal year 2016 second quarter cash dividend of $0.38 per ordinary share, representing a 25 percent improvement over the preceding year. This quarterly declaration is consistent with the dividend declaration made by the company in June. Medtronic has raised its annual dividend payment for the past 38 successive years, and is a constituent of the S&P 500 Dividend Aristocrats index. The dividend is payable on October 16, 2015, to shareholders of record at the close of business on September 25, 2015. While a portion of the dividend may be treated for U.S. tax purposes as a return of capital, the company anticipates that, over time, its dividend will be treated completely as a return of earnings.
Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators, implantable cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, and peripheral vascular intervention products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
